We are a proven team dedicated to developing immunology-based therapies with significant opportunities to address unmet patient needs and transform lives. We act purposefully and urgently to enable patients with autoimmune diseases to reimagine their lives.
Enabling patients with autoimmune diseases to reimagine life
Rapidly advancing our programs for multiple autoimmune diseases.
Obexelimab, an investigational drug, is a bifunctional monoclonal antibody designed to bind to both CD19- and FcγRIIb, which are broadly present across the B cell lineage. Co-engagement of these targets results in suppression of B cell activity, a key contributor to many autoimmune diseases. Obexelimab is advancing through clinical trials with the potential to address the unmet medical needs of patients.
See our progress
Serving Patients and Caregivers
With curiosity and compassion, we strive to understand patients’ experiences to introduce transformative new therapies that help them realize the lives they intended.
Read our commitment
Leading With Intention
Our commitment to being a leader in the development and commercialization of immunology-based therapies is clear. With our exceptional team, we believe we can.
Explore the Zenas Experience